Advisors Asset Management Inc. boosted its stake in Arrowhead Pharmaceuticals by 94.6% during the first quarter.

Source: https://www.etfdailynews.com/2023/04/29/arrowhead-pharmaceuticals-inc-nasdaqarwr-stock-position-lifted-by-zurcher-kantonalbank-zurich-cantonalbank/

Amgen is in the hunt with olpasiran, a gene-silencing drug licensed from Arrowhead Pharmaceuticals that has reached late-stage clinical development.

Source: https://medcitynews.com/2023/06/eli-lilly-cardiovascular-disease-in-vivo-gene-editing/

Arizona State Retirement System’s holdings in Arrowhead Pharmaceuticals were worth $1,151,000 as of its most recent filing with the SEC.

Source: https://www.etfdailynews.com/2023/05/14/arizona-state-retirement-system-grows-position-in-arrowhead-pharmaceuticals-inc-nasdaqarwr/

Belpointe Asset Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth approximately $27,000.

Source: https://www.etfdailynews.com/2023/06/10/arrowhead-pharmaceuticals-inc-nasdaqarwr-shares-purchased-by-geode-capital-management-llc/

Chardan Capital reissued a “buy” rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Friday, February 10th.

Source: https://www.americanbankingnews.com/2023/02/28/arrowhead-pharmaceuticals-inc-nasdaqarwr-shares-acquired-by-point72-hong-kong-ltd.html

Citigroup started coverage on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 19th.

Source: https://www.dailypolitical.com/2023/12/04/arrowhead-pharmaceuticals-nasdaqarwr-receives-new-coverage-from-analysts-at-bank-of-america.html

Creative Planning’s holdings in Arrowhead Pharmaceuticals were worth $482,000 as of its most recent filing with the Securities and Exchange Commission.

Source: https://www.etfdailynews.com/2023/02/03/arrowhead-pharmaceuticals-inc-nasdaqarwr-position-increased-by-creative-planning/

Finally, Assetmark Inc. grew its position in Arrowhead Pharmaceuticals by 13.6% in the 3rd quarter.

Source: https://www.americanbankingnews.com/2023/01/27/barclays-plc-has-9-86-million-holdings-in-arrowhead-pharmaceuticals-inc-nasdaqarwr.html

Finally, assumed coverage on Arrowhead Pharmaceuticals in a report on Thursday, March 16th.

Source: https://www.etfdailynews.com/2023/03/31/arrowhead-pharmaceuticals-inc-nasdaqarwr-short-interest-up-19-0-in-march/

Finally, initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Thursday.

Source: https://www.etfdailynews.com/2023/03/18/arrowhead-pharmaceuticals-nasdaqarwr-reaches-new-1-year-low-at-24-73/

Geode Capital Management LLC’s holdings in Arrowhead Pharmaceuticals were worth $80,047,000 as of its most recent SEC filing.

Source: https://www.etfdailynews.com/2023/06/10/arrowhead-pharmaceuticals-inc-nasdaqarwr-shares-purchased-by-geode-capital-management-llc/

HighTower Advisors LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 4.9% during the 1st quarter.

Source: https://www.etfdailynews.com/2023/07/02/assenagon-asset-management-s-a-acquires-shares-of-423307-arrowhead-pharmaceuticals-inc-nasdaqarwr/

Royal Bank of Canada lowered their target price on Arrowhead Pharmaceuticals from $83.00 to $77.00 and set an “outperform” rating for the company in a research note on Tuesday, February 7th.

Source: https://www.etfdailynews.com/2023/05/01/bank-of-montreal-can-has-642000-position-in-arrowhead-pharmaceuticals-inc-nasdaqarwr/

Swiss National Bank owned approximately 0.21% of Arrowhead Pharmaceuticals worth $7,988,000 at the end of the most recent quarter.

Source: https://www.americanbankingnews.com/2023/11/25/arrowhead-pharmaceuticals-inc-nasdaqarwr-shares-acquired-by-swiss-national-bank.html

Texas Permanent School Fund Corp grew its holdings in Arrowhead Pharmaceuticals by 36.5% in the 1st quarter.

Source: https://www.etfdailynews.com/2023/08/05/arrowhead-pharmaceuticals-inc-nasdaqarwr-position-cut-by-nisa-investment-advisors-llc/

Vanguard Group Inc. grew its position in shares of Arrowhead Pharmaceuticals by 0.8% during the third quarter.

Source: https://www.dailypolitical.com/2023/04/29/arrowhead-pharmaceuticals-nasdaqarwr-coverage-initiated-by-analysts-at-sumitomo-mitsui-financial-group.html